

4-22-2025

## A Comparison of Anti-Citrullinated Peptide Antibody, Lactate Dehydrogenase, Zinc and Copper in Sera of Patients with Rheumatoid Arthritis and Healthy Control: A Cross Sectional Study

Fatima Qasim AL-Obaidy

*Department of Applied Science, Branch of Applied Chemistry, University of Technology, Baghdad, Iraq,*  
tamtamfeef91@gmail.com

Abdulnasser M. Al-Gebori

*Department of Applied Science, Branch of Applied Chemistry, University of Technology, Baghdad, Iraq*

Mohammed Hadi Munshed Alosami

*Department of Medicine, Colleges of Medicine, University of Baghdad, Baghdad, Iraq,*  
Mohammad\_alosami@yahoo.com

Follow this and additional works at: <https://bsj.uobaghdad.edu.iq/home>

---

### How to Cite this Article

AL-Obaidy, Fatima Qasim; Al-Gebori, Abdulnasser M.; and Alosami, Mohammed Hadi Munshed (2025) "A Comparison of Anti-Citrullinated Peptide Antibody, Lactate Dehydrogenase, Zinc and Copper in Sera of Patients with Rheumatoid Arthritis and Healthy Control: A Cross Sectional Study," *Baghdad Science Journal*: Vol. 22: Iss. 4, Article 7.

DOI: <https://doi.org/10.21123/bsj.2024.9538>

This Article is brought to you for free and open access by Baghdad Science Journal. It has been accepted for inclusion in Baghdad Science Journal by an authorized editor of Baghdad Science Journal.



## RESEARCH ARTICLE

# A Comparison of Anti-Citrullinated Peptide Antibody, Lactate Dehydrogenase, Zinc and Copper in Sera of Patients with Rheumatoid Arthritis and Healthy Control: A Cross Sectional Study

Fatima Qasim AL-Obaidy<sup>1,\*</sup>, Abdunnasser M. Al-Gebori<sup>1</sup>,  
Mohammed Hadi Munshed Alosami<sup>2</sup>

<sup>1</sup> Department of Applied Science, Branch of Applied Chemistry, University of Technology, Baghdad, Iraq

<sup>2</sup> Department of Medicine, Colleges of Medicine, University of Baghdad, Baghdad, Iraq

## ABSTRACT

Rheumatoid Arthritis (RA) is a chronic, systemic autoimmune disease associated with synovial tissue proliferation, cartilage destruction and pannus formation. The study aimed to determine the link among each anticyclic anti-citrullinated peptide antibody (ACPA), lactate dehydrogenase (LDH), zinc (Zn), and copper (Cu) levels in rheumatoid arthritis (RA) patients and healthy control. Across sectional study was carried out at the Baghdad Teaching Hospital in Baghdad Iraq, and involved 110 patients (95 females and 15 men), who were matched for age and sex with 40 healthy controls (28 females and 12 males). Patients with RA were diagnosed by a specialist rheumatologist utilizing ACR/EULAR criteria in 2010. According to the type of disease-modifying anti-rheumatic drug therapy used—biologic (bDMARDs), conventional (cDMARDs), and combined (DMARDs)—patients in this study were split into three subgroups. Zn, Cu, and LDH were quantified using a spectrophotometer (AAS), whilst serum ACPA was assessed using an enzyme-linked immunosorbent assay (ELISA). The results showed that there was a significant rise in all subgroups of ACPAs ( $p < 0.001$ ), Zn ( $p < 0.001$ ), and Cu ( $p < 0.001$ ) when compared to the healthy control, but no significant differences across subgroups. LDH levels increased significantly in the chemotherapy and bio-chemotherapy subgroups as compared to healthy controls, but LDH levels decreased significantly in the biology subgroup when compared to the chemotherapy and bio-chemotherapy subgroups. Changing therapy types has no effect on raising levels of ACPA, Zn, and Cu, however, it has an effect on LDH levels. The Biology subgroup showed no significant difference among RA patients subgroup and healthy control.

**Keywords:** Anti-citrullinated peptide antibodies, Autoimmunity, Copper, Lactate dehydrogenase, Rheumatoid arthritis (RA), Synovitis, Zinc

## Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease that can damage the tissue lining the joints the skin, eyes, and other organ in some cases. The severity of the disease varies from

patient to patient. The risk factors include gender, genetics, age, and exposure to the environment (air pollutants, cigarette smoking, and occupational exposure). The onset of this disease is usually between the ages of 35 and 60 years, with periods of remission, exacerbation.<sup>1,2</sup> The global prevalence

Received 19 September 2023; revised 19 February 2024; accepted 21 February 2024.  
Available online 22 April 2025

\* Corresponding author.

E-mail addresses: [tamtamfeef91@gmail.com](mailto:tamtamfeef91@gmail.com) (F. Q. AL-Obaidy), [Abdunnasser.m.abdullah@uotechnology.edu.iq](mailto:Abdunnasser.m.abdullah@uotechnology.edu.iq) (A. M. Al-Gebori), [Mohammad\\_alosami@yahoo.com](mailto:Mohammad_alosami@yahoo.com) (M. H. Munshed Alosami).

<https://doi.org/10.21123/bsj.2024.9538>

2411-7986/© 2025 The Author(s). Published by College of Science for Women, University of Baghdad. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

of RA was estimated in a recent meta-analysis as 0.46%, while the prevalence rate is 1% in Iraq.<sup>3,4</sup> Autoantibodies are one of the distinguishing features of rheumatoid arthritis (RA). A lot of research has been done on anti-citrullinated protein antibodies (ACPAs).<sup>5</sup> Autoantibodies targeting acetylated proteins, such as anti-acetylated peptide antibody (AAPA),<sup>6</sup> and others have more recently been added to existing autoantibody systems that recognize post-translationally changed proteins.<sup>7</sup> ACPAs, which are autoantibodies that attack citrullinated peptides, were identified as highly specific markers present in RA patients and first described in 1964.<sup>8</sup> In the inflammatory process, citrullinated proteins play an important role in stimulating the production of antibodies. ACPA is produced by B plasma cells, and Fibrin is the major citrullinated protein in RA joints.<sup>9</sup> The lactate dehydrogenase (LDH) enzyme is present in almost all tissues and it's required in the final step of anaerobic glycolysis. It is released during tissue injury and inflammation.<sup>10</sup> Inflammation in RA and RA-like disorders is not restricted to joints and affects many organs of the body, so it is worth studying an inflammatory marker such as S.LDH, which is involved in multi-system inflammation.<sup>11</sup> Trace elements that include Zn, Cu, and other have been identified as one of these components, and their homeostasis is critical to controlling several parts of the inflammatory and immunological systems. Zn has been shown to play a role in maturation, cell cycle progression and differentiation.<sup>12</sup> It may have a role in arthritis because it is crucial for the innate and adaptive immune systems, as well as bone development, regeneration and controlling a number of inflammatory response components.<sup>13</sup> Cu may also influence the oxidant defense system by functioning as a catalytic cofactor and coordinating with Se and Zn, which are also responsible for adequate cartilage mineralization and the production of elastin and collagen structures, according to research.<sup>14</sup> In addition, tissue regeneration, bone formation, ATP production, and hemoglobin synthesis furthermore, it is a crucial component of the central nervous system's development.<sup>15</sup> Abnormal trace elements concentrations are associated with the regulate of gene expression inflammatory response, bone metabolism and regulate of transcriptional like cyclooxygenase-2, matrix metalloprotease 2 and inducible nitric oxide synthase, which are potentially associated with RA.<sup>16</sup> Hence, the objective of this study was investigate the role of ACPA, Zinc, Copper and LDH in Rheumatoid arthritis patients and identify a predictor for treatment response, which in turn can guide early treatment decisions among middle-aged and older of Iraqi patients.

## Materials and methods

Five milliliters of blood were withdrawn from 110 RA patients (95 females and 15 males) with a range age of 36–65 years, and 40 healthy controls (28 females and 12 males) matched in age and sex to the patients. Furthermore, the samples were placed in the gel tubes. After that, they were spun in a centrifuge at 3000 rpm for 10 minutes, then separated and transferred to 0.5 ml Eppendorf tubes, which were subsequently frozen at  $-20^{\circ}\text{C}$  for further analysis. The study was conducted in Baghdad Teaching Hospital/Medical City between September 15, 2022, and March 25, 2023. Diagnosis, treatment, and follow-up of all patients were performed in this clinic and young individuals, or individuals with a history of disability, psychological and mental diseases, malignant tumors, autoimmune diseases were excluded from the study. The patients were divided into three subgroups: (1) biological treatment subgroup (consisted of thirty-eight patients on the bDMARDs treatment), (2) conventional cDMARD subgroup (thirty-eight patients received MTX) and (3) combined DMARD subgroup (thirty-four patients had received biology and chemotherapy). The human ACPAs were determined by using Sandwich ELISA (Biorad, Germany) from the SunLong Biotech kit (China). LDH levels were determined using a commercial kit (BIOLAB) that was measured by a spectrophotometer (BIOLAB instrument). The conversion of NADH to NAD<sup>+</sup> results in a decrease in absorbance. LDH activity in the specimen is directly proportional to the wavelength of 340 nm. Whereas the determination of Zn utilized the direct colorimetric test without deproteinizing the sample by using a commercial kit (LTA, Italy), and copper concentrations were determined using a commercial kit (LTA, Italy), which was measured by a spectrophotometer (CECELL 3000).

## Ethical considerations

Ethical approval was obtained from the University of Technology ethical committee for this study. In addition, Verbal consent was obtained from all participants prior to their involvement.

## Statistical analysis

The data was analyzed using SPSS-V26, with parametric data provided as means  $\pm$  standard error. Age, gender, and differences between patients and control were compared using independent samples T test. Serum ACPAs, LDH, Zn, and Cu levels were compared between RA patients and healthy control.

**Table 1.** Showed demographic characteristics of patients.

Characteristics	Patients n = 110 Mean (min-max)
Age (years)	51 (36-75)
Male	15 (13.7%)
Female	95 (86.36%)
	Treatment
Biology	38 (34.5%)
Chemotherapy	38 (34.5%)
Biochemotherapy	34 (30.9%)

**Table 2.** Levels of ACPA in sera of healthy control and RA patients.

Parameter	Healthy control Mean ± SE	Patients Mean ± SE	P-value
ACPAs (ng/mL)	19.98 ± 3.29	51.05 ± 5.613	0.0001**

**Table 3.** Serum human ACPAs levels in RA subgroup patients and apparently healthy control.

	ACPAs (ng/mL)		
Healthy control Mean ± SE	Biology Mean ± SE	Chemotherapy Mean ± SE	Biochemotherapy Mean ± SE
19.98 ± 3.29	57.11 ± 4.56	49.76 ± 5.48	46.27 ± 3.18

## Results

In this study, 110 RA patients (95 female and 15% male,) were compared to 40 healthy controls. Patients ranged in age from 50 to 59 years old on average. Female gender outnumbered male gender (5:1) as shown in [Table 1](#).

The mean ± SE of ACPA in healthy control and RA patients were 19.98 ± 3.29 ng/mL and 51.05 ± 5.613 ng/mL respectively, as showed in [Table 2](#).

Statistical analysis of ACPAs levels distributed among RA patients' subgroup and healthy control groups by ANOVA. The mean ± SE of ACPA in biology 57.11 ± 4.56 ng/mL more than chemotherapy and biochemotherapy (49.76 ± 5.48, 46.27 ± 3.18) ng/mL respectively when compared with healthy controls (19.98 ± 3.29) ng/mL, as shown in [Table 3](#).

[Table 4](#) reveals that there were highly significant variations in ACPA levels through RA subgroup patients (biology, chemotherapy, and biochemotherapy) as compared to healthy control ( $P \leq 0.0001$ ). Multiple comparison showed there was no significant difference between subgroups with each other.

ACPAs: anticitrulinated peptide Antibodies, HC: healthy control, P-value: probability value, ng/mL: Nanograms per milliliter.

Results in the current study demonstrated that the levels of LDH in RA subgroup biology are [106.0 ± 7.87 IU/L, chemotherapy 137.8 ± 11.65 IU/L,

**Table 4.** Multiple comparisons of ACPA levels between patients' subgroups and healthy control.

Parameters	Group treatments	p-value
ACPAs (ng/mL)	HC vs. Biology	0.0001**
	HC vs. Chemotherapy	0.0001**
	HC vs. Bio-chemotherapy	0.0001**
	Biology vs. Chemotherapy	0.2
	Biology vs. Biochemotherapy	0.2
	Chemotherapy vs. Biochemotherapy	0.4

\*\* Highly Significant at  $P \leq 0.001$ .

**Table 5.** Serum human LDH levels in patients and healthy.

	LDH (IU/L)			
Healthy control Mean ± SE	Biology Mean ± SE	Chemotherapy Mean ± SE	Biochemotherapy Mean ± SE	
100.5 ± 12.71	106.0 ± 7.87	137.8 ± 11.65	154.5 ± 3.82	

LDH: lactate dehydrogenase, IU/International units.

**Table 6.** Multiple comparisons for LDH in studied group treatments.

Parameters	Group treatments	p-value
LDH (IU/L)	HC vs. Biology	0.96
	HC vs. Chemotherapy	0.02*
	HC vs. Bio-chemotherapy	0.0004**
	Biology vs. Chemotherapy	0.08*
	Biology vs. Biochemotherapy	0.002**
	Chemotherapy vs. Biochemotherapy	0.59

\* Significant at  $P \leq 0.05$ .

\*\* Highly Significant at  $P \leq 0.01$ .

LDH: Lactate dehydrogenase, HC: healthy control, IU/international units per Liter.

biochemotherapy 154.5 ± 3.82 IU/L and healthy control 100.5 ± 12.71] as shown in [Table 5](#).

Results in [Table 6](#) showed a significant increase in the serum levels of LDH in chemotherapy and biochemotherapy subgroup patients of RA compared to healthy controls, while there was no significant difference between biology subgroups compared to healthy control ( $p = 0.96$ ). Whereas multiple comparisons of subgroups with each other showed a significant decrease in biology subgroup as compared to the chemotherapy subgroup and biochemotherapy subgroup. Moreover, there is no significant difference between the chemotherapy subgroup compared to biochemotherapy subgroup.

Results demonstrated that the levels of Zinc in RA subgroup [biology 103.4 ± 6.22 μg/dl, chemotherapy 110.4 ± 7.04 μg/dl and biochemotherapy 109.1 ± 7.78 μg/dl] higher than zinc level in the HC group 82.35 ± 7.74 by AONVA as investigate in [Table 7](#).

Results showed a significant increase in level of zinc in biology subgroup and a highly significant increase of chemotherapy and biochemotherapy as compared to healthy control. Multiple comparisons revealed that

**Table 7.** Serum human Zinc levels in patients and healthy.

Zinc ( $\mu\text{g/dL}$ )			
Healthy control	Biology	Mean $\pm$ SE	Biochemotherapy
Mean $\pm$ SE	Mean $\pm$ SE	Mean $\pm$ SE	Mean $\pm$ SE
82.35 $\pm$ 7.74	103.4 $\pm$ 6.22	110.4 $\pm$ 7.04	109.1 $\pm$ 7.78

Microgram per deciliter ( $\mu\text{g/dl}$ ), healthy control (HC).

**Table 8.** Multiple comparisons for Zinc in RA patients' subgroup and healthy control.

Parameters	Group treatments	p-value
Zinc ( $\mu\text{g/dl}$ )	HC vs. Biology	0.011*
	HC vs. Chemotherapy	0.001**
	HC vs. Bio-chemotherapy	0.005**
	Biology vs. Chemotherapy	0.45
	Biology vs. Biochemotherapy	0.56
	Chemotherapy vs. Biochemotherapy	0.12

\* Significant at  $P \leq 0.05$ .

\*\* Highly Significant at  $P \leq 0.01$ .

**Table 9.** Serum human Cu levels in patients and apparently healthy control.

Copper ( $\mu\text{g/dL}$ )			
Healthy control	Biology	Chemotherapy	Biochemotherapy
Mean $\pm$ SE	Mean $\pm$ SE	Mean $\pm$ SE	Mean $\pm$ SE
93.84 $\pm$ 3.19	251.5 $\pm$ 7.14	251.0 $\pm$ 10.75	265.6 $\pm$ 8.57

Copper: (Cu), microgram per deciliter ( $\mu\text{g/dl}$ ), healthy control (HC).

were no significant difference between subgroup with each other are revealed in [Table 8](#).

Microgram per deciliter ( $\mu\text{g/dl}$ ), healthy control (HC).

The results demonstrated that the levels of Cu in RA subgroup were [biology 251.5  $\pm$  7.14  $\mu\text{g/dl}$ , chemotherapy 251.0  $\pm$  10.75  $\mu\text{g/dl}$  and biochemotherapy 265.6  $\pm$  8.57  $\mu\text{g/dl}$ ] higher than Cu level in the healthy control group 93.84  $\pm$  3.19  $\mu\text{g/dl}$  as shown in [Table 9](#).

Results revealed that there was a highly significant increase in levels of Cu through all RA subgroup patients as compared to healthy control ( $P \leq 0.0001$ ). Multiple comparison showed there was no significant difference between subgroups with each other's as showed in [Table 10](#).

In RA, Pearson's correlation was utilized to examine the possible correlation between ACPA and (LDH, Zn and Cu). Results showed a significant positive correlation between ACPA and LDH ( $R = 0.624$ ,  $P = 0.001$ ) in the biology subgroup, whereas no significant correlation between ACPA with other parameters in different subgroups of RA patients as shown in [Table 11](#).

**Table 10.** Multiple comparisons for copper in RA patients' subgroup and healthy control.

Parameters	Group treatments	p-value
Copper ( $\mu\text{g/dl}$ )	HC vs. Biology	0.0001**
	HC vs. Chemotherapy	0.0001**
	HC vs. Bio-chemotherapy	0.0001**
	Biology vs. Chemotherapy	0.98
	Biology vs. Biochemotherapy	0.76
	Chemotherapy vs. Biochemotherapy	0.73

\*\* Highly Significant at  $P \leq 0.01$ .

Copper: (Cu), microgram per deciliter ( $\mu\text{g/dl}$ ), healthy control (HC).

## Discussion


Results of the current study demonstrated a highly significant increase in levels of ACPA in RA patients. A great percentage of RA patients produce ACPA as a result of early RA's lack of tolerance and the increase of the anti-citrullinated antibody response, which is significantly associated with the development of arthritis.<sup>17,18</sup> Additional studies have found that anticitrullinated peptide antibodies are linked to Human Leukocyte Antigen – DR isotype (HLA-DR) shared epitope status.<sup>19</sup> The current study's findings are consistent with data from other research studies conducted throughout the world which show that the primary target of ACPA in the pre-clinical phase of RA is osteoclast precursor and osteoclast cells located in bone marrow. Furthermore, ACPA can cause bone destruction by inducing proinflammatory cytokines such as (IL-1, IL-12), which spread to the joint and cause inflammation of the synovial.<sup>20</sup> Moreover, the study found that is no significant difference in patients receiving only chemotherapy or biological treatment, or combined biological with chemotherapy treatment. This is consistent with previous research reported that individual reach RA diagnosis; the ACPA repertoire remains relatively stable over time with small changes in ACPA levels and only occasional seroconversion.<sup>21</sup> The main reason is that ACPA-positive B cells undergo multiple cycles of germinal center reaction, thus accumulating cell mutations and carrying out homotypic transformation. The citrulline-specific immune response can produce long-lived plasma cells and a stable titer of ACPAs.<sup>22</sup> In addition, the ACPA reactivity level significantly decline in beginning use of DMARD treatment (during the first three month), and then remains stable.<sup>23</sup> Furthermore, the ACPA subtypes differ depending on the different antigens and antibody isotypes. Targeted therapy can only target some of them, which is a limitation of targeted biology therapy.<sup>24</sup> In addition, the lack of consciousness about rheumatic disease among Iraqis, a lack of training among Iraqi health care

**Table 11.** The correlation between ACPAs (ng/ml) and other parameters in in studied group treatments.

Parameters	ACPAs (ng/ml)					
	Biology		Chemotherapy		Biochemotherapy	
	R	P-value	R	P-value	R	P-value
Cu	-0.116	0.18	0.102	0.65	-0.125	0.57
Zn	-0.294	0.60	0.060	0.79	-0.004	0.98
LDH	0.623**	0.0019**	-0.013	0.95	0.041	0.85

\*\* Highly Significant at  $P \leq 0.01$ .

Copper: (Cu), Zinc (Zn), Lactate dehydrogenase (LDH).

**Fig. 1.** Plot displays ACPA-LDH correlation in RA biology subgroup.

professionals, and it ought to be added that patients have very limited access to biology treatment, which is provided only by the national Ministry of Health.<sup>25</sup> Niitsue *et al.*<sup>26</sup> reported that elevated LDH levels were roughly 97% of RA patients that treated by MTX. In normal inflammation, CD8+ T lymphocytes (CD8) can release proinflammatory cytokines such as (IL-1, IL-12) and cellular breakdown mediators. In RA, CD8 activity is dependent on LDH activity, and B cell activation is similarly impacted by LDH activity, the FX11 inhibitor (Lactate Dehydrogenase Inhibitor) and LDHA inhibitor, GSK2837808A, have been shown to reduce the inflammatory potential of CD8+ and B lymphocytes by inhibiting LDH.<sup>27</sup> The data of the present study revealed an increase in the level of zinc in RA due to the fact that zinc is a necessary element and dietary supplement that has been shown to lower the incidence in rheumatoid arthritis sufferers, so zinc is required for the down regulation of inflammatory responses. In addition, zinc supplements in combination with MTX prevent damage of intestinal and protect enterocyte cell proliferation during RA treatment.<sup>28</sup> Moreover, Serum Cu and Zn levels increase in RA patients due to antagonistic relationship between copper and zinc, with overdoses reducing copper absorption,<sup>29</sup> for these

reasons mentioned above, patients are provided with zinc during treatment. Nonetheless, our findings were consistent with other studies by Dhiaj *et al.*,<sup>30</sup> The results in our study demonstrated that the levels of Cu in the RA subgroup increase compared to healthy controls because, during rheumatoid arthritis inflammation, biomarkers cytokines such as interleukin-1 (IL-1) regulate the secretion of ceruloplasmin in liver cells, content of copper in the blood increases as ceruloplasmin is transported from the liver cell to the serum.<sup>31,32</sup> In addition, the results showed a significant positive correlation between ACPA and LDH in biology subgroup, indicating that the fact that sodium lactate can cause CD4+ T helper cells to change into the Th17 subset and that ACPA-producing B cells play a role in the inflammatory process of RA suggests that lactic acid (LA) may indirectly contribute to the proinflammatory process of ACPA production.<sup>27</sup> In addition, the biology drug mechanism that genetically engineered monoclonal antibodies and receptor constructs were specifically designed to target extracellular mediators of inflammation with high specificity and do not have the capability of crossing the plasma membrane of a cell.<sup>33</sup> Moreover, monocarboxylate transporter(MCTs) are important transporters that are crucial for the

intracellular production and transmembrane transport of LA. The transfer of LA into or out of cells by MCT1 depends on the metabolic status of cells<sup>34</sup> These findings are consistent with a recent study by Cunningham *et al.*, **which** found that patients with ACPA-positive RA have a larger clinical therapeutic impact than patients with ACPA-negative RA.<sup>35,36</sup> The study had limitations, including limited sample size for direct comparison of RA subgroup, single-center open-labeled design without double-blinding, potential information bias from physicians. Larger, longer-term studies with objective outcome measures are needed to confirm findings.

## Conclusion

Most RA patients produce ACPA, and treatment doesn't affect ACPA levels. LDH levels increase with severity of RA. Zinc and copper are essential trace elements for metabolism and immune function. Zinc supports healthy cartilage growth and immune response, while copper ions increase joint inflammation. DMARD or b DMARD therapy choice depends on patient's comorbidities and contraindications.

## Acknowledgment

The authors are grateful to the Applied Chemistry Branch, Department of Applied Sciences, University of Technology, Baghdad Teaching Hospital staff as well as the Blood Bank staff for providing and facilitating our findings.

## Authors' declaration

- Conflicts of Interest: None.
- We hereby confirm that all the Figures and Tables in the manuscript are ours. Furthermore, any Figures and images, that are not ours, have been included with the necessary permission for republication, which is attached to the manuscript.
- Authors sign on ethical consideration's approval.
- No animal studies are present in the manuscript.
- No potentially identified images or data are present in the manuscript.
- Ethical Clearance: The project was approved by the local ethical committee at University of Technology.

## Authors' contributions

M. H. M participated in specifying the title of the research and also diagnosed patients according to

disease-specific criteria of this study. A. M. participated in specifying the title of the research and studying the variation of parameters and their relationship with disease. F. Q. collected specimens, prepared the samples to work, determined levels of all parameters using many approaches in many devices, and conducted a statistical study for research.

## References

1. Bullock J, Rizvi SA, Saleh AM, Ahmed SS, DP Do, Ansari RA, *et al.* Rheumatoid arthritis: a brief overview of the treatment. *Med Princ Pract.* 2019;27(6):501-507. <https://doi.org/10.1159/000493390>.
2. Gravallesse EM, Firestein GS. Rheumatoid arthritis - common origins, divergent mechanisms. *N Engl J Med.* 2023;388(6):529-542. <https://doi.org/10.1056/NEJMra2103726>.
3. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. *Rheumatol Int.* 2021;41:863-877.
4. Al-Rawi ZS, Alazzawi AJ, Alajili FM, Alwakil R. Rheumatoid arthritis in population samples in Iraq. *Ann Rheum Dis.* 1978;37(1):73-75. <https://doi.org/10.1136%2Fard.37.1.73>.
5. Camille Brewer, Tobias V Lanz, Caryn R Hale, Gregory D Sepich-Poore, Cameron Martino, Austin D Swafford, *et al.* Oral mucosal breaks trigger anti-citrullinated bacterial and human protein antibody responses in rheumatoid arthritis. *Sci Transl Med.* 2023;15(684):76-84. <https://doi.org/10.1126/scitranslmed.abq8476>.
6. Studenic P, Alunno A, Sieghart D, Bang H, Aletaha D, Blüml S. *et al.* Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. *Ther Adv Musculoskelet Dis.* 2021;13:1-15. <https://doi.org/10.1177/1759720X211022533>.
7. Sokolova MV, Schett G, Steffen U. Autoantibodies in rheumatoid arthritis: historical background and novel findings. *Clinic Rev Allerg Immunol.* 2022;63:138-151. <https://doi.org/10.1007/s12016-021-08890-1>.
8. Yi Wu CH, Yu Yang H, Haung Lai J. Anti-Citrullinated protein antibodies in patients with rheumatoid arthritis: Biological effects and mechanisms of immunopathogenesis. *Int J Mol Sci.* 2020;21(11):1-23. <https://doi.org/10.3390/ijms21114015>.
9. Scherer HU, van der Woude D, Toes REM. From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis. *Nat Rev Rheumatol.* 2022;18:371-383. <https://doi.org/10.1038/s41584-022-00786-4>.
10. Farhana A, Lappin SL. Biochemistry, Lactate Dehydrogenase. In: StatPearls Publishing, Treasure Island (FL). Europe PMID. 2022:32491468. <https://europepmc.org/article/nbk/nbk557536#free-full-text>.
11. Manosalva C, Quiroga J, Hidalgo AI, Alarcon P, Anseoleaga N, Hidalgo MA, *et al.* Role of lactate in inflammatory processes: Friend or foe. *Front Immunol.* 2022;12:799-808. <https://doi.org/10.3389/fimmu.2021.808799>.
12. Ma Y, Zhang Xu, Fan D, Xia Q, Wang M, Pan F. Common trace metals in rheumatoid arthritis: A systematic review and meta-analysis. *J Trace Elem Med Biol.* 2019;56:81-89. <https://doi.org/10.1016/j.jtemb.2019.07.007>.

13. Frangos T, Maret W. Zinc and cadmium in the aetiology and pathogenesis of osteoarthritis and rheumatoid arthritis. *Nutrients*. 2021;13(1):23–45. <https://doi.org/10.3390/nu13010053>.
14. Marreiro DD, Cruz KJ, Morais JB, Beserra JB, Severo JS, De Oliveira AR. Zinc and oxidative stress: current mechanisms. *Antioxidants*. 2017;6(2):1124–1129. <https://doi.org/10.3390/antiox6020024>.
15. Mirończuk-Chodakowska I, Socha K, Zujko ME, Terlikowska KM, Borawska MH, Witkowska AM. Copper, Manganese, Selenium and Zinc in wild-growing edible mushrooms from the eastern territory of “green lungs of poland”: Nutritional and toxicological implications. *Int J Environ Res Public Health*. 2019;16(19):14–36. <https://doi.org/10.3390/ijerph16193614>.
16. Christensen DG, Xie X, Basisty N, Byrnes J, McSweeney S, Schilling B, *et al*. Post-translational protein acetylation: an elegant mechanism for bacteria to dynamically regulate metabolic functions. *Front Microbiol*. 2019;10:1604–1626. <https://doi.org/10.3389/fmicb.2019.01604>.
17. Kurowska W, Kuca-Warnawin EH, Radzikowska A, Maśliński W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. *Centr Eur J Immunol*. 2017;42(4):390–398. <https://doi.org/10.5114/ceji.2017.72807>.
18. Sonigra A, Nel HJ, Wehr P, Ramnoruth N, Patel S, van Schie KA, *et al*. Thomas R. Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis. *JCI Insight*. 2022;7(20):1–17. <https://doi.org/10.1172/jci.insight.160964>.
19. Van Gaalen FA, Van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, *et al*. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. *Arthritis Rheumatol*. 2004;50:2113–2121. <https://doi.org/10.1002/art.20316>.
20. Zhang P, Zhang X, Xu F, Xu W, Zhu H. Elevated expression of interleukin-27, IL-35, and decreased IL-12 in patients with thyroid-associated ophthalmopathy. *Graefes Arch Clin Exp Ophthalmol*. 2023;261:1091–1100. <https://doi.org/10.1007/s00417-022-05856-7>.
21. Chirivi RG, van Rosmalen JW, van der Linden M, Euler M, Schmetts G, Bogatkevich G, *et al*. Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases. *Cell Mol Immunol*. 2021;18:1528–1544. <https://doi.org/10.1038/s41423-020-0381-3>.
22. Catrina A, Krishnamurthy A, Rethi B. Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis. *RMD open*. 2021;7(1):1–9. <https://doi.org/10.1136/rmdopen-2020-001228>.
23. Malmström V, Grönwall C. The parallel worlds of ACPA-positive and RF-positive B cells. *Nat Rev Rheumatol*. 2018;14:626–628. <https://doi.org/10.1038/s41584-018-0094-5>.
24. Jonsson MK, Hensvold AH, Hansson M, Aga AB, Sexton J, Mathsson-Alm L, *et al*. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy. *Arthritis Res Ther*. 2018;20:1–11. <https://doi.org/10.1186/s13075-018-1635-7>.
25. Al-Ani N, Gorial F, Yasiry D, Al Derwibee F, Abbas Humadi Y, Sunna N, *et al*. Clinical outcomes in Iraqi patients with rheumatoid arthritis following earlier or later treatment with etanercept. *Open Access Rheumatol.: Res Rev*. 2021;13:57–62. <https://doi.org/10.2147/OARRR.S300838>.
26. Niitsu N, Okamoto M, Nakamine H, Hirano M. Clinico-pathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. *Cancer Sci*. 2010;101(5):1309–1313. <https://doi.org/10.1111/j.1349-7006.2010.01517.x>.
27. Wang Q, Asenso J, Xiao N, Gao J, Xiao F, Kuai J, *et al*. Lactic acid regulation: A potential therapeutic option in rheumatoid arthritis. *J Immunol Res*. 2022;2022:1–11. <https://doi.org/10.1155/2022/2280973>.
28. Al-Hindawi M, Al-Gebori A, Alosami M. Tenascin-C and Interleukin-17 Up-regulation in Axial Spondyloarthritis Patients. *Rheumatology (Bulgaria)*. 2023;30(4):3–11. <https://doi.org/10.35465/30.4.2022.pp3-11>.
29. Xin L, Yang X, Cai G, Fan D, Xia Q, Liu L, *et al*. Serum levels of copper and zinc in patients with rheumatoid arthritis: a meta-analysis. *Biol Trace Elem Res*. 2015;168:1–10. <https://doi.org/10.1007/s12011-015-0325-4>.
30. Al-Timimi DJ, Al-Sharbatti SS, Al-Najjar F. Zinc deficiency among a healthy population in Baghdad, Iraq. *Saudi Med J*. 2005;26(11):1777–1781. <https://europepmc.org/article/med/16311665>.
31. Liu Y, Zhu J, Xu L, Wang B, Lin W, Luo Y. Copper regulation of immune response and potential implications for treating orthopedic disorders. *Front Mol Biosci*. 2022;9:1065265. <https://doi.org/10.3389/fmolb.2022.1065265>.
32. Olewi Ahmed R, ZGAIR Ayaid Khadem. Estimation levels of CTHRC1 and some cytokines in Iraqi patients with Rheumatoid Arthritis. *Baghdad Sci J*. 2023;20(3):928–936. <https://doi.org/10.21123/bsj.2023.8036>.
33. Findeisen KE, Sewell J, Ostor AJ. Biological therapies for rheumatoid arthritis: an overview for the clinician. *Biol: Targets Ther*. 2021;15:343–352. <https://doi.org/10.2147/BTT.S252575>.
34. Halestrap AP, Wilson MC. The monocarboxylate transporter family—role and regulation. *IUBMB life*. 2012;64(2):109–119. <https://doi.org/10.1002/iub.572>.
35. Cunningham KY, Hur B, Gupta VK, Arment CA, Wright KA, Mason TG, *et al*. Patients with ACPA-positive and ACPA-negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with disease activity. *Sci Rep*. 2023;13:5360. <https://doi.org/10.1038/s41598-023-32428-4>.
36. Mohammed N U G, Khaleel F M, Gorial F I. The Role of serum chitinase-3-like 1 protein (YKL-40) level and its correlation with proinflammatory cytokine in patients with rheumatoid arthritis. *Baghdad Sci J*. 2022;19(5):1014–1020. <http://dx.doi.org/10.21123/bsj.2022.6293>.

## ارتباط الأجسام المضادة للبيتيد المضاد للسيترولينات والانزيم المزيل للفوسفات القاعدي المرضى المصابين بالتهاب المفاصل الرثوي

فاطمة قاسم العبيدي<sup>1</sup>، عبدالناصر محمد الجبوري<sup>1</sup>، محمد هادي منشد العصامي<sup>2</sup>

<sup>1</sup> فرع الكيمياء التطبيقية، قسم العلوم التطبيقية، الجامعة التكنولوجية، بغداد، العراق.

<sup>2</sup> قسم الطب، كلية الطب، جامعة بغداد، بغداد، العراق.

### الخلاصة

المفاصل الروماتويدي (RA) هو مرض مناعي ذاتي جهازي مزمن يرتبط بتكاثر الأنسجة الزليلية وتكوين السبل. كان الغرض من هذه الدراسة هو تحديد العلاقة بين هذه العوامل ومستويات الأجسام المضادة للبيتيد المضاد للسيترولين (ACPA)، والانزيم النازع لهيدروجين اللاكتات (LDH)، والزنك (Zn)، والنحاس (Cu) في مرضى التهاب المفاصل الروماتويدي (RA) أجريت الدراسة في مستشفى بغداد التعليمي في بغداد، العراق، وشارك فيها 110 مريضاً (95 أنثى و15 رجلاً)، الذين تمت مطابقتهم من حيث العمر والجنس مع 40 من الأشخاص الأصحاء (28 أنثى و12 ذكراً). تم تشخيص المرضى الذين يعانون من التهاب المفاصل الروماتويدي من قبل مجموعة اطباء الروماتيزم المتخصص باستخدام معايير ACR/EULAR في عام 2010. وفقاً لنوع العلاج المضاد للروماتيزم المعدل للمرض المستخدم - البيولوجي (bDMARDs)، التقليدي (cDMARDs)، والمختلط - (DMARDs). تم تقسيم المرضى في هذه الدراسة إلى ثلاث مجموعات فرعية. تم قياس كمية الزنك والنحاس وLDH باستخدام مقياس الطيف الضوئي (AAS)، في حين تم تقييم مصل ACPA باستخدام مقايصة الامتصاص المناعي المرتبط بالانزيم (ELISA) أظهرت النتائج وجود ارتفاع ملحوظ في جميع المجموعات الفرعية لـ (p<0.001) ACPAs، الزنك (p<0.001)، والنحاس (p<0.001) بالمقارنة مع مجموعة الأشخاص الأصحاء، ولكن لا توجد فروق ذات دلالة إحصائية بين المجموعات الفرعية. زادت مستويات LDH بشكل ملحوظ في المجموعات الفرعية للعلاج الكيميائي والعلاج الكيميائي الحيوي بالمقارنة مع الأصحاء، ولكن مستويات LDH انخفضت بشكل ملحوظ في المجموعة الفرعية للبيولوجيا بالمقارنة مع المجموعات الفرعية للعلاج الكيميائي والعلاج الكيميائي الحيوي. ليس لتغيير أنواع العلاج أي تأثير على رفع مستويات ACPA، والزنك، والنحاس، إلا أنه له تأثير على مستويات LDH لم تظهر المجموعة الفرعية للبيولوجيا أي فرق كبير بين المرضى والأشخاص الأصحاء.

**الكلمات المفتاحية:** الأجسام المضادة البيبتيدية المضادة للسيترولين، المناعة الذاتية، النحاس، الانزيم النازع لهيدروجين اللاكتات، التهاب المفاصل الروماتويدي (RA)، التهاب الغشاء المفصلي، الزنك.